Copeptin and insulin resistance: effect modification by age and 11 β-HSD2 activity in a population-based study

S. Canivell, M. Mohaupt, D. Ackermann, M. Pruijm, I. Guessous, G. Ehret, G. Escher, A. Pechère-Bertschi, B. Vogt, O. Devuyst, M. Burnier, P. Y. Martin, B. Ponte, M. Bochud

Research output: Contribution to journalArticle

Abstract

Purpose: Arginine vasopressin (AVP) may be involved in metabolic syndrome (MetS) by altering liver glycogenolysis, insulin and glucagon secretion, and pituitary ACTH release. Moreover, AVP stimulates the expression of 11β-hydroxysteroid-dehydrogenase-type 2 (11β-HSD2) in mineralocorticosteroid cells. We explored whether apparent 11β-HSD2 activity, estimated using urinary cortisol-to-cortisone ratio, modulates the association between plasma copeptin, as AVP surrogate, and insulin resistance/MetS in the general adult population. Methods: This was a multicentric, family-based, cross-sectional sample of 1089 subjects, aged 18–90 years, 47% men, 13.4% MetS, in Switzerland. Mixed multivariable linear and logistic regression models were built to investigate the association of insulin resistance (HOMA-IR)/fasting glucose and MetS/Type 2 Diabetes with copeptin, while considering potential confounders or effect modifiers into account. Stratified results by age and 11β-HSD2 activity were presented as appropriate. Results: Plasma copeptin was higher in men [median 5.2, IQR (3.7–7.8) pmol/L] than in women [median 3.0, IQR (2.2–4.3) pmol/L], P < 0.0001. HOMA-IR was positively associated with copeptin after full adjustment if 11β-HSD2 activity was high [β (95% CI) = 0.32 (0.17–0.46), P < 0.001] or if age was high [β (95% CI) = 0.34 (0.20–0.48), P < 0.001], but not if either 11β-HSD2 activity or age was low. There was a positive association of type 2 diabetes with copeptin [OR (95% CI) = 2.07 (1.10–3.89), P = 0.024), but not for MetS (OR (95% CI) = 1.12 (0.74–1.69), P = 0.605), after full adjustment. Conclusions: Our data suggest that age and apparent 11β-HSD2 activity modulate the association of copeptin with insulin resistance at the population level but not MeTS or diabetes. Further research is needed to corroborate these results and to understand the mechanisms underlying these findings.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalJournal of Endocrinological Investigation
DOIs
StateAccepted/In press - Dec 12 2017
Externally publishedYes

Fingerprint

11-beta-Hydroxysteroid Dehydrogenases
Insulin Resistance
Arginine Vasopressin
Population
Social Adjustment
Type 2 Diabetes Mellitus
Logistic Models
Glycogenolysis
Cortisone
Glucagon
Switzerland
Adrenocorticotropic Hormone
Hydrocortisone
copeptins
Linear Models
Fasting
Insulin
Glucose
Liver
Research

Keywords

  • 11-β hydroxysteroid dehydrogenase type 2 enzyme
  • Aging
  • Copeptin
  • Insulin resistance
  • Interaction

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Copeptin and insulin resistance : effect modification by age and 11 β-HSD2 activity in a population-based study. / Canivell, S.; Mohaupt, M.; Ackermann, D.; Pruijm, M.; Guessous, I.; Ehret, G.; Escher, G.; Pechère-Bertschi, A.; Vogt, B.; Devuyst, O.; Burnier, M.; Martin, P. Y.; Ponte, B.; Bochud, M.

In: Journal of Endocrinological Investigation, 12.12.2017, p. 1-10.

Research output: Contribution to journalArticle

Canivell, S, Mohaupt, M, Ackermann, D, Pruijm, M, Guessous, I, Ehret, G, Escher, G, Pechère-Bertschi, A, Vogt, B, Devuyst, O, Burnier, M, Martin, PY, Ponte, B & Bochud, M 2017, 'Copeptin and insulin resistance: effect modification by age and 11 β-HSD2 activity in a population-based study', Journal of Endocrinological Investigation, pp. 1-10. https://doi.org/10.1007/s40618-017-0807-7
Canivell, S. ; Mohaupt, M. ; Ackermann, D. ; Pruijm, M. ; Guessous, I. ; Ehret, G. ; Escher, G. ; Pechère-Bertschi, A. ; Vogt, B. ; Devuyst, O. ; Burnier, M. ; Martin, P. Y. ; Ponte, B. ; Bochud, M. / Copeptin and insulin resistance : effect modification by age and 11 β-HSD2 activity in a population-based study. In: Journal of Endocrinological Investigation. 2017 ; pp. 1-10.
@article{50a1c0ce614c412ea68df69829d19559,
title = "Copeptin and insulin resistance: effect modification by age and 11 β-HSD2 activity in a population-based study",
abstract = "Purpose: Arginine vasopressin (AVP) may be involved in metabolic syndrome (MetS) by altering liver glycogenolysis, insulin and glucagon secretion, and pituitary ACTH release. Moreover, AVP stimulates the expression of 11β-hydroxysteroid-dehydrogenase-type 2 (11β-HSD2) in mineralocorticosteroid cells. We explored whether apparent 11β-HSD2 activity, estimated using urinary cortisol-to-cortisone ratio, modulates the association between plasma copeptin, as AVP surrogate, and insulin resistance/MetS in the general adult population. Methods: This was a multicentric, family-based, cross-sectional sample of 1089 subjects, aged 18–90 years, 47{\%} men, 13.4{\%} MetS, in Switzerland. Mixed multivariable linear and logistic regression models were built to investigate the association of insulin resistance (HOMA-IR)/fasting glucose and MetS/Type 2 Diabetes with copeptin, while considering potential confounders or effect modifiers into account. Stratified results by age and 11β-HSD2 activity were presented as appropriate. Results: Plasma copeptin was higher in men [median 5.2, IQR (3.7–7.8) pmol/L] than in women [median 3.0, IQR (2.2–4.3) pmol/L], P < 0.0001. HOMA-IR was positively associated with copeptin after full adjustment if 11β-HSD2 activity was high [β (95{\%} CI) = 0.32 (0.17–0.46), P < 0.001] or if age was high [β (95{\%} CI) = 0.34 (0.20–0.48), P < 0.001], but not if either 11β-HSD2 activity or age was low. There was a positive association of type 2 diabetes with copeptin [OR (95{\%} CI) = 2.07 (1.10–3.89), P = 0.024), but not for MetS (OR (95{\%} CI) = 1.12 (0.74–1.69), P = 0.605), after full adjustment. Conclusions: Our data suggest that age and apparent 11β-HSD2 activity modulate the association of copeptin with insulin resistance at the population level but not MeTS or diabetes. Further research is needed to corroborate these results and to understand the mechanisms underlying these findings.",
keywords = "11-β hydroxysteroid dehydrogenase type 2 enzyme, Aging, Copeptin, Insulin resistance, Interaction",
author = "S. Canivell and M. Mohaupt and D. Ackermann and M. Pruijm and I. Guessous and G. Ehret and G. Escher and A. Pech{\`e}re-Bertschi and B. Vogt and O. Devuyst and M. Burnier and Martin, {P. Y.} and B. Ponte and M. Bochud",
year = "2017",
month = "12",
day = "12",
doi = "10.1007/s40618-017-0807-7",
language = "English (US)",
pages = "1--10",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Editrice Kurtis s.r.l.",

}

TY - JOUR

T1 - Copeptin and insulin resistance

T2 - effect modification by age and 11 β-HSD2 activity in a population-based study

AU - Canivell, S.

AU - Mohaupt, M.

AU - Ackermann, D.

AU - Pruijm, M.

AU - Guessous, I.

AU - Ehret, G.

AU - Escher, G.

AU - Pechère-Bertschi, A.

AU - Vogt, B.

AU - Devuyst, O.

AU - Burnier, M.

AU - Martin, P. Y.

AU - Ponte, B.

AU - Bochud, M.

PY - 2017/12/12

Y1 - 2017/12/12

N2 - Purpose: Arginine vasopressin (AVP) may be involved in metabolic syndrome (MetS) by altering liver glycogenolysis, insulin and glucagon secretion, and pituitary ACTH release. Moreover, AVP stimulates the expression of 11β-hydroxysteroid-dehydrogenase-type 2 (11β-HSD2) in mineralocorticosteroid cells. We explored whether apparent 11β-HSD2 activity, estimated using urinary cortisol-to-cortisone ratio, modulates the association between plasma copeptin, as AVP surrogate, and insulin resistance/MetS in the general adult population. Methods: This was a multicentric, family-based, cross-sectional sample of 1089 subjects, aged 18–90 years, 47% men, 13.4% MetS, in Switzerland. Mixed multivariable linear and logistic regression models were built to investigate the association of insulin resistance (HOMA-IR)/fasting glucose and MetS/Type 2 Diabetes with copeptin, while considering potential confounders or effect modifiers into account. Stratified results by age and 11β-HSD2 activity were presented as appropriate. Results: Plasma copeptin was higher in men [median 5.2, IQR (3.7–7.8) pmol/L] than in women [median 3.0, IQR (2.2–4.3) pmol/L], P < 0.0001. HOMA-IR was positively associated with copeptin after full adjustment if 11β-HSD2 activity was high [β (95% CI) = 0.32 (0.17–0.46), P < 0.001] or if age was high [β (95% CI) = 0.34 (0.20–0.48), P < 0.001], but not if either 11β-HSD2 activity or age was low. There was a positive association of type 2 diabetes with copeptin [OR (95% CI) = 2.07 (1.10–3.89), P = 0.024), but not for MetS (OR (95% CI) = 1.12 (0.74–1.69), P = 0.605), after full adjustment. Conclusions: Our data suggest that age and apparent 11β-HSD2 activity modulate the association of copeptin with insulin resistance at the population level but not MeTS or diabetes. Further research is needed to corroborate these results and to understand the mechanisms underlying these findings.

AB - Purpose: Arginine vasopressin (AVP) may be involved in metabolic syndrome (MetS) by altering liver glycogenolysis, insulin and glucagon secretion, and pituitary ACTH release. Moreover, AVP stimulates the expression of 11β-hydroxysteroid-dehydrogenase-type 2 (11β-HSD2) in mineralocorticosteroid cells. We explored whether apparent 11β-HSD2 activity, estimated using urinary cortisol-to-cortisone ratio, modulates the association between plasma copeptin, as AVP surrogate, and insulin resistance/MetS in the general adult population. Methods: This was a multicentric, family-based, cross-sectional sample of 1089 subjects, aged 18–90 years, 47% men, 13.4% MetS, in Switzerland. Mixed multivariable linear and logistic regression models were built to investigate the association of insulin resistance (HOMA-IR)/fasting glucose and MetS/Type 2 Diabetes with copeptin, while considering potential confounders or effect modifiers into account. Stratified results by age and 11β-HSD2 activity were presented as appropriate. Results: Plasma copeptin was higher in men [median 5.2, IQR (3.7–7.8) pmol/L] than in women [median 3.0, IQR (2.2–4.3) pmol/L], P < 0.0001. HOMA-IR was positively associated with copeptin after full adjustment if 11β-HSD2 activity was high [β (95% CI) = 0.32 (0.17–0.46), P < 0.001] or if age was high [β (95% CI) = 0.34 (0.20–0.48), P < 0.001], but not if either 11β-HSD2 activity or age was low. There was a positive association of type 2 diabetes with copeptin [OR (95% CI) = 2.07 (1.10–3.89), P = 0.024), but not for MetS (OR (95% CI) = 1.12 (0.74–1.69), P = 0.605), after full adjustment. Conclusions: Our data suggest that age and apparent 11β-HSD2 activity modulate the association of copeptin with insulin resistance at the population level but not MeTS or diabetes. Further research is needed to corroborate these results and to understand the mechanisms underlying these findings.

KW - 11-β hydroxysteroid dehydrogenase type 2 enzyme

KW - Aging

KW - Copeptin

KW - Insulin resistance

KW - Interaction

UR - http://www.scopus.com/inward/record.url?scp=85037729787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037729787&partnerID=8YFLogxK

U2 - 10.1007/s40618-017-0807-7

DO - 10.1007/s40618-017-0807-7

M3 - Article

C2 - 29235050

AN - SCOPUS:85037729787

SP - 1

EP - 10

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

ER -